Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Feb 26, 2022; 14(2): 183-199
Published online Feb 26, 2022. doi: 10.4252/wjsc.v14.i2.183
Published online Feb 26, 2022. doi: 10.4252/wjsc.v14.i2.183
Extracellular vesicles from hypoxia-preconditioned mesenchymal stem cells alleviates myocardial injury by targeting thioredoxin-interacting protein-mediated hypoxia-inducible factor-1α pathway
Cheng-Yu Mao, Tian-Tian Zhang, Dong-Jiu Li, En Zhou, Yu-Qi Fan, Qing He, Chang-Qian Wang, Jun-Feng Zhang, Department of Cardiology, Shanghai Ninth People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200010, China
Author contributions: Mao CY, Zhang TT, Li DJ, and Zhou E contributed equally to this work, performed the experiments, and reviewed and edited the manuscript; Fan YQ and He Q wrote the paper; Zhang JF, and Wang CQ conceived of and funded the study; all authors read and approved the final manuscript.
Supported by National Natural Science Foundation of China , No. 81870264 and No. 81470546 ; the Shanghai Committee of Science and Technology , No. 18411950500 ; the Major Disease Joint Project of Shanghai Health System , No. 2014ZYJB0501 ; and Talent Cultivation Project of The Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine , No. JC202005 .
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of Shanghai Ninth People’s Hospital.
Institutional animal care and use committee statement: All animal procedures were approved by the Shanghai Ninth People’s Hospital Institutional Ethics Committee and conducted in accordance with the guidelines of the Directive 2010/63/EU of the European Parliament.
Conflict-of-interest statement: The authors declare that they have no competing interests regarding this study.
Data sharing statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jun-Feng Zhang, MD, PhD, Professor, Department of Cardiology, Shanghai Ninth People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine, No. 280 Mohe Road, Baoshan District, Shanghai 200010, China.
Received: October 13, 2021
Peer-review started: October 13, 2021
First decision: November 8, 2021
Revised: November 29, 2021
Accepted: January 25, 2022
Article in press: January 25, 2022
Published online: February 26, 2022
Processing time: 134 Days and 20.8 Hours
Peer-review started: October 13, 2021
First decision: November 8, 2021
Revised: November 29, 2021
Accepted: January 25, 2022
Article in press: January 25, 2022
Published online: February 26, 2022
Processing time: 134 Days and 20.8 Hours
Core Tip
Core Tip: Extracellular vesicles (EVs) from adipose-derived mesenchymal stem cells treated with hypoxia preconditioning improve tolerance toward myocardial infarction or hypoxic conditions and alleviate the degree of cardiomyocyte apoptosis until reperfusion therapy. The anti-apoptotic effects may result from EV miR-224-5p targeting thioredoxin-interacting protein (TXNIP) and subsequent TXNIP-mediated hypoxia-inducible factor-1 alpha ubiquitination and degradation via the chromosomal region maintenance-1-mediated nuclear transport pathway.